Publication — IRIC

WD40 repeat domain proteins: a novel target class?

Antagonism of protein-protein interactions (PPIs) with small molecules is becoming more feasible as a therapeutic approach. Successful PPI inhibitors tend to target proteins containing deep peptide-binding grooves or pockets rather than the more common large, flat protein interaction surfaces. Here, we review one of the most abundant PPI domains in the human proteome, the WD40 repeat (WDR) domain, which has a central peptide-binding pocket and is a member of the β-propeller domain-containing protein family. Recently, two WDR domain-containing proteins, WDR5 and EED, as well as other β-propeller domains have been successfully targeted by potent, specific, cell-active, drug-like chemical probes. Could WDR domains be a novel target class for drug discovery? Although the research is at an early stage and therefore not clinically validated, cautious optimism is justified, as WDR domain-containing proteins are involved in multiple disease-associated pathways. The druggability and structural diversity of WDR domain binding pockets suggest that understanding how to target this prevalent domain class will open up areas of disease biology that have so far resisted drug discovery efforts.

Publication date
November 1, 2017
Principal Investigators
Schapira M, Tyers M, Torrent M, Arrowsmith CH
PubMed reference
Nat Rev Drug Discov 2017;16(11):773-786
PubMed ID
29026209
Affiliation
Structural Genomics Consortium, University of Toronto, Toronto, 101 College St, MaRS South Tower, Suite 700, Ontario M5G 1L7, Canada.